CN1752107A - 一种抗apoA I、apoB抗体制备方法以及用于检测apoA I、apoB的试剂盒 - Google Patents
一种抗apoA I、apoB抗体制备方法以及用于检测apoA I、apoB的试剂盒 Download PDFInfo
- Publication number
- CN1752107A CN1752107A CN 200510061277 CN200510061277A CN1752107A CN 1752107 A CN1752107 A CN 1752107A CN 200510061277 CN200510061277 CN 200510061277 CN 200510061277 A CN200510061277 A CN 200510061277A CN 1752107 A CN1752107 A CN 1752107A
- Authority
- CN
- China
- Prior art keywords
- apob
- apoa
- weight ratio
- antigen
- reagent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 101150102415 Apob gene Proteins 0.000 title claims abstract description 140
- 239000003153 chemical reaction reagent Substances 0.000 title claims abstract description 101
- 238000002360 preparation method Methods 0.000 title description 14
- 101100379247 Salmo trutta apoa1 gene Proteins 0.000 title description 5
- 101100055841 Danio rerio apoa1 gene Proteins 0.000 claims abstract description 113
- 239000000427 antigen Substances 0.000 claims abstract description 80
- 102000036639 antigens Human genes 0.000 claims abstract description 80
- 108091007433 antigens Proteins 0.000 claims abstract description 80
- 210000002966 serum Anatomy 0.000 claims abstract description 52
- 238000000034 method Methods 0.000 claims abstract description 37
- 239000007788 liquid Substances 0.000 claims abstract description 33
- 241001465754 Metazoa Species 0.000 claims abstract description 23
- 238000012360 testing method Methods 0.000 claims abstract description 18
- 239000013543 active substance Substances 0.000 claims description 43
- 230000003078 antioxidant effect Effects 0.000 claims description 41
- 239000003963 antioxidant agent Substances 0.000 claims description 40
- 239000012482 calibration solution Substances 0.000 claims description 39
- 238000013016 damping Methods 0.000 claims description 29
- 239000012530 fluid Substances 0.000 claims description 29
- 239000003085 diluting agent Substances 0.000 claims description 28
- 229920000642 polymer Polymers 0.000 claims description 28
- 239000003795 chemical substances by application Substances 0.000 claims description 25
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 25
- 238000006243 chemical reaction Methods 0.000 claims description 23
- 238000001556 precipitation Methods 0.000 claims description 23
- 239000008213 purified water Substances 0.000 claims description 23
- 239000000203 mixture Substances 0.000 claims description 21
- 239000003112 inhibitor Substances 0.000 claims description 13
- 239000012747 synergistic agent Substances 0.000 claims description 13
- 102000004895 Lipoproteins Human genes 0.000 claims description 12
- 108090001030 Lipoproteins Proteins 0.000 claims description 12
- 244000309466 calf Species 0.000 claims description 12
- 239000011159 matrix material Substances 0.000 claims description 10
- 210000002381 plasma Anatomy 0.000 claims description 10
- 238000005238 degreasing Methods 0.000 claims description 9
- 239000004094 surface-active agent Substances 0.000 claims description 9
- 230000000890 antigenic effect Effects 0.000 claims description 8
- 238000000605 extraction Methods 0.000 claims description 7
- 239000008280 blood Substances 0.000 claims description 6
- 239000000284 extract Substances 0.000 claims description 6
- 239000006228 supernatant Substances 0.000 claims description 6
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 claims description 5
- 238000009472 formulation Methods 0.000 claims description 4
- 238000005520 cutting process Methods 0.000 claims description 3
- 238000009991 scouring Methods 0.000 claims description 3
- 238000011091 antibody purification Methods 0.000 claims description 2
- 238000003149 assay kit Methods 0.000 claims 2
- 230000000694 effects Effects 0.000 abstract description 6
- 230000008569 process Effects 0.000 abstract description 6
- 238000004519 manufacturing process Methods 0.000 abstract description 3
- 230000003053 immunization Effects 0.000 abstract 1
- 239000000376 reactant Substances 0.000 abstract 1
- 239000003109 Disodium ethylene diamine tetraacetate Substances 0.000 description 27
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 27
- 235000019301 disodium ethylene diamine tetraacetate Nutrition 0.000 description 27
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 24
- 229940098773 bovine serum albumin Drugs 0.000 description 24
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 21
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 21
- 239000004255 Butylated hydroxyanisole Substances 0.000 description 18
- 239000008118 PEG 6000 Substances 0.000 description 18
- 229920002584 Polyethylene Glycol 6000 Polymers 0.000 description 18
- 235000019282 butylated hydroxyanisole Nutrition 0.000 description 18
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 18
- 229940043253 butylated hydroxyanisole Drugs 0.000 description 18
- -1 polyoxyethylene Polymers 0.000 description 18
- 239000000872 buffer Substances 0.000 description 16
- KZKAYEGOIJEWQB-UHFFFAOYSA-N 1,3-dibromopropane;n,n,n',n'-tetramethylhexane-1,6-diamine Chemical group BrCCCBr.CN(C)CCCCCCN(C)C KZKAYEGOIJEWQB-UHFFFAOYSA-N 0.000 description 15
- 229920000209 Hexadimethrine bromide Polymers 0.000 description 15
- 229950007870 hexadimethrine bromide Drugs 0.000 description 15
- 230000000844 anti-bacterial effect Effects 0.000 description 14
- 239000003899 bactericide agent Substances 0.000 description 14
- 230000036039 immunity Effects 0.000 description 14
- 239000002953 phosphate buffered saline Substances 0.000 description 14
- 238000001228 spectrum Methods 0.000 description 14
- 239000003242 anti bacterial agent Substances 0.000 description 13
- 229940088710 antibiotic agent Drugs 0.000 description 13
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 13
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 12
- 241001494479 Pecora Species 0.000 description 11
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 11
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- 239000000499 gel Substances 0.000 description 8
- 238000002347 injection Methods 0.000 description 8
- 239000007924 injection Substances 0.000 description 8
- 238000002156 mixing Methods 0.000 description 8
- 238000004321 preservation Methods 0.000 description 8
- INEWUCPYEUEQTN-UHFFFAOYSA-N 3-(cyclohexylamino)-2-hydroxy-1-propanesulfonic acid Chemical compound OS(=O)(=O)CC(O)CNC1CCCCC1 INEWUCPYEUEQTN-UHFFFAOYSA-N 0.000 description 7
- 102000018619 Apolipoproteins A Human genes 0.000 description 7
- 108010027004 Apolipoproteins A Proteins 0.000 description 7
- 235000017858 Laurus nobilis Nutrition 0.000 description 7
- 235000005212 Terminalia tomentosa Nutrition 0.000 description 7
- 244000125380 Terminalia tomentosa Species 0.000 description 7
- 238000001514 detection method Methods 0.000 description 7
- 108010025964 lipophorin Proteins 0.000 description 7
- 239000003921 oil Substances 0.000 description 7
- JXKPEJDQGNYQSM-UHFFFAOYSA-M sodium propionate Chemical compound [Na+].CCC([O-])=O JXKPEJDQGNYQSM-UHFFFAOYSA-M 0.000 description 7
- 235000010334 sodium propionate Nutrition 0.000 description 7
- 239000004324 sodium propionate Substances 0.000 description 7
- 229960003212 sodium propionate Drugs 0.000 description 7
- 108010027006 Apolipoproteins B Proteins 0.000 description 6
- 102000018616 Apolipoproteins B Human genes 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 229920001213 Polysorbate 20 Polymers 0.000 description 6
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 6
- 239000012528 membrane Substances 0.000 description 6
- 239000008363 phosphate buffer Substances 0.000 description 6
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 6
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 6
- 238000000967 suction filtration Methods 0.000 description 6
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 5
- 108010010234 HDL Lipoproteins Proteins 0.000 description 5
- 102000015779 HDL Lipoproteins Human genes 0.000 description 5
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- UETNIIAIRMUTSM-UHFFFAOYSA-N Jacareubin Natural products CC1(C)OC2=CC3Oc4c(O)c(O)ccc4C(=O)C3C(=C2C=C1)O UETNIIAIRMUTSM-UHFFFAOYSA-N 0.000 description 4
- 108010007622 LDL Lipoproteins Proteins 0.000 description 4
- 102000007330 LDL Lipoproteins Human genes 0.000 description 4
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 4
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 4
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 4
- 239000004141 Sodium laurylsulphate Substances 0.000 description 4
- 210000001015 abdomen Anatomy 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 238000003018 immunoassay Methods 0.000 description 4
- 230000001926 lymphatic effect Effects 0.000 description 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N monobenzene Natural products C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 4
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 4
- NCEXYHBECQHGNR-QZQOTICOSA-N sulfasalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-QZQOTICOSA-N 0.000 description 4
- 229960001940 sulfasalazine Drugs 0.000 description 4
- NCEXYHBECQHGNR-UHFFFAOYSA-N sulfasalazine Natural products C1=C(O)C(C(=O)O)=CC(N=NC=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-UHFFFAOYSA-N 0.000 description 4
- 206010003645 Atopy Diseases 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 210000001715 carotid artery Anatomy 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 230000007812 deficiency Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- PJDVOLYULHZZAG-UHFFFAOYSA-N ethylmercury Chemical compound CC[Hg] PJDVOLYULHZZAG-UHFFFAOYSA-N 0.000 description 3
- 238000000760 immunoelectrophoresis Methods 0.000 description 3
- 230000005847 immunogenicity Effects 0.000 description 3
- 239000011259 mixed solution Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- PODWXQQNRWNDGD-UHFFFAOYSA-L sodium thiosulfate pentahydrate Chemical compound O.O.O.O.O.[Na+].[Na+].[O-]S([S-])(=O)=O PODWXQQNRWNDGD-UHFFFAOYSA-L 0.000 description 3
- 102100040202 Apolipoprotein B-100 Human genes 0.000 description 2
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 2
- 239000004322 Butylated hydroxytoluene Substances 0.000 description 2
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- GHKOFFNLGXMVNJ-UHFFFAOYSA-N Didodecyl thiobispropanoate Chemical compound CCCCCCCCCCCCOC(=O)CCSCCC(=O)OCCCCCCCCCCCC GHKOFFNLGXMVNJ-UHFFFAOYSA-N 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 2
- KFSLWBXXFJQRDL-UHFFFAOYSA-N Peracetic acid Chemical compound CC(=O)OO KFSLWBXXFJQRDL-UHFFFAOYSA-N 0.000 description 2
- 108010071390 Serum Albumin Proteins 0.000 description 2
- 102000007562 Serum Albumin Human genes 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 208000034953 Twin anemia-polycythemia sequence Diseases 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 125000001931 aliphatic group Chemical group 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 2
- 229940095259 butylated hydroxytoluene Drugs 0.000 description 2
- 208000026106 cerebrovascular disease Diseases 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 229960000935 dehydrated alcohol Drugs 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 229960004756 ethanol Drugs 0.000 description 2
- 238000001502 gel electrophoresis Methods 0.000 description 2
- YMAWOPBAYDPSLA-UHFFFAOYSA-N glycylglycine Chemical compound [NH3+]CC(=O)NCC([O-])=O YMAWOPBAYDPSLA-UHFFFAOYSA-N 0.000 description 2
- 229960002897 heparin Drugs 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 230000037189 immune system physiology Effects 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 229910001629 magnesium chloride Inorganic materials 0.000 description 2
- 229910052748 manganese Inorganic materials 0.000 description 2
- 239000011572 manganese Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 229920002401 polyacrylamide Polymers 0.000 description 2
- 235000013824 polyphenols Nutrition 0.000 description 2
- XOJVVFBFDXDTEG-UHFFFAOYSA-N pristane Chemical compound CC(C)CCCC(C)CCCC(C)CCCC(C)C XOJVVFBFDXDTEG-UHFFFAOYSA-N 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 239000002002 slurry Substances 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- MGSRCZKZVOBKFT-UHFFFAOYSA-N thymol Chemical compound CC(C)C1=CC=C(C)C=C1O MGSRCZKZVOBKFT-UHFFFAOYSA-N 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 238000005199 ultracentrifugation Methods 0.000 description 2
- 210000000689 upper leg Anatomy 0.000 description 2
- 238000001291 vacuum drying Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- IHPYMWDTONKSCO-UHFFFAOYSA-N 2,2'-piperazine-1,4-diylbisethanesulfonic acid Chemical compound OS(=O)(=O)CCN1CCN(CCS(O)(=O)=O)CC1 IHPYMWDTONKSCO-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- LVQFQZZGTZFUNF-UHFFFAOYSA-N 2-hydroxy-3-[4-(2-hydroxy-3-sulfonatopropyl)piperazine-1,4-diium-1-yl]propane-1-sulfonate Chemical compound OS(=O)(=O)CC(O)CN1CCN(CC(O)CS(O)(=O)=O)CC1 LVQFQZZGTZFUNF-UHFFFAOYSA-N 0.000 description 1
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 1
- 108010082126 Alanine transaminase Proteins 0.000 description 1
- 101710095342 Apolipoprotein B Proteins 0.000 description 1
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 1
- 239000008001 CAPS buffer Substances 0.000 description 1
- 239000008000 CHES buffer Substances 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 108010008488 Glycylglycine Proteins 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- OWXMKDGYPWMGEB-UHFFFAOYSA-N HEPPS Chemical compound OCCN1CCN(CCCS(O)(=O)=O)CC1 OWXMKDGYPWMGEB-UHFFFAOYSA-N 0.000 description 1
- 239000007996 HEPPS buffer Substances 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 101000889953 Homo sapiens Apolipoprotein B-100 Proteins 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 1
- MKWKNSIESPFAQN-UHFFFAOYSA-N N-cyclohexyl-2-aminoethanesulfonic acid Chemical compound OS(=O)(=O)CCNC1CCCCC1 MKWKNSIESPFAQN-UHFFFAOYSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 239000007990 PIPES buffer Substances 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 239000005844 Thymol Substances 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- DPDMMXDBJGCCQC-UHFFFAOYSA-N [Na].[Cl] Chemical compound [Na].[Cl] DPDMMXDBJGCCQC-UHFFFAOYSA-N 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- LPQOADBMXVRBNX-UHFFFAOYSA-N ac1ldcw0 Chemical compound Cl.C1CN(C)CCN1C1=C(F)C=C2C(=O)C(C(O)=O)=CN3CCSC1=C32 LPQOADBMXVRBNX-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 125000005037 alkyl phenyl group Chemical group 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 229940037003 alum Drugs 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 239000003945 anionic surfactant Substances 0.000 description 1
- 150000001450 anions Chemical group 0.000 description 1
- 230000000923 atherogenic effect Effects 0.000 description 1
- 230000003143 atherosclerotic effect Effects 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 239000012888 bovine serum Substances 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000005253 cladding Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 229940043257 glycylglycine Drugs 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 230000000951 immunodiffusion Effects 0.000 description 1
- 230000002434 immunopotentiative effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- 238000003760 magnetic stirring Methods 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 150000003016 phosphoric acids Chemical class 0.000 description 1
- 229940093429 polyethylene glycol 6000 Drugs 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 229960000790 thymol Drugs 0.000 description 1
- 238000004879 turbidimetry Methods 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Landscapes
- Investigating Or Analysing Biological Materials (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Description
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2005100612776A CN100357325C (zh) | 2005-10-23 | 2005-10-23 | 一种抗apoA I、apoB抗体制备方法以及用于检测apoA I、apoB的试剂盒 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2005100612776A CN100357325C (zh) | 2005-10-23 | 2005-10-23 | 一种抗apoA I、apoB抗体制备方法以及用于检测apoA I、apoB的试剂盒 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2006101327020A Division CN101135687B (zh) | 2005-10-23 | 2005-10-23 | 一种用于检测apoA I、apoB的试剂盒 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1752107A true CN1752107A (zh) | 2006-03-29 |
CN100357325C CN100357325C (zh) | 2007-12-26 |
Family
ID=36679119
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB2005100612776A Active CN100357325C (zh) | 2005-10-23 | 2005-10-23 | 一种抗apoA I、apoB抗体制备方法以及用于检测apoA I、apoB的试剂盒 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN100357325C (zh) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101799475A (zh) * | 2010-03-31 | 2010-08-11 | 浙江伊利康生物技术有限公司 | 一种载脂蛋白e检测试剂 |
CN101000349B (zh) * | 2006-12-31 | 2011-08-24 | 浙江伊利康生物技术有限公司 | 前白蛋白检测试剂盒 |
CN110981861A (zh) * | 2019-12-18 | 2020-04-10 | 苏州博源医疗科技有限公司 | 一种氯氮平衍生物及其制备方法与氯氮平检测试剂 |
CN111426845A (zh) * | 2020-04-07 | 2020-07-17 | 中拓生物有限公司 | 一种血清载脂蛋白b测定试剂盒及其制备方法和应用 |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10729788B2 (en) | 2015-12-10 | 2020-08-04 | The Regents Of The University Of California | Compositions and methods for treating or ameliorating neuroinflammation, neurodegeneration, neuropathic pain, and migraine |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH08113593A (ja) * | 1994-08-25 | 1996-05-07 | Masao Umemoto | 界面活性剤を用いるタンパク凝集反応の増強法 |
NZ334589A (en) * | 1996-09-11 | 2000-07-28 | Pharmacia & Upjohn Ab | Aqueous two-phase system for purifying apolipoproteins |
-
2005
- 2005-10-23 CN CNB2005100612776A patent/CN100357325C/zh active Active
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101000349B (zh) * | 2006-12-31 | 2011-08-24 | 浙江伊利康生物技术有限公司 | 前白蛋白检测试剂盒 |
CN101799475A (zh) * | 2010-03-31 | 2010-08-11 | 浙江伊利康生物技术有限公司 | 一种载脂蛋白e检测试剂 |
CN110981861A (zh) * | 2019-12-18 | 2020-04-10 | 苏州博源医疗科技有限公司 | 一种氯氮平衍生物及其制备方法与氯氮平检测试剂 |
CN110981861B (zh) * | 2019-12-18 | 2022-08-30 | 苏州博源医疗科技有限公司 | 一种氯氮平衍生物及其制备方法与氯氮平检测试剂 |
CN111426845A (zh) * | 2020-04-07 | 2020-07-17 | 中拓生物有限公司 | 一种血清载脂蛋白b测定试剂盒及其制备方法和应用 |
CN111426845B (zh) * | 2020-04-07 | 2021-06-15 | 中拓生物有限公司 | 一种血清载脂蛋白b测定试剂盒及其制备方法和应用 |
Also Published As
Publication number | Publication date |
---|---|
CN100357325C (zh) | 2007-12-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1685236A (zh) | N-11端截短的β-淀粉样蛋白的单克隆抗体、组合物、方法和用途 | |
CN1285514A (zh) | 检测抗丙型肝炎病毒抗体的药盒 | |
CN1646910A (zh) | 白血病、前白血病或非白血病性恶性血液疾病的判定方法以及诊断药 | |
CN1832964A (zh) | 用结合脑钠尿肽前体分子氨基酸41-46的单克隆抗体检测脑钠尿肽前体分子的方法 | |
CN1053265A (zh) | 人体C3b/C4b受体(CR1) | |
CN1752107A (zh) | 一种抗apoA I、apoB抗体制备方法以及用于检测apoA I、apoB的试剂盒 | |
CN1636058A (zh) | 新型丙氨酸转氨酶及其应用方法 | |
CN1914333A (zh) | 极低密度脂蛋白残粒(vldl残粒)中的胆固醇的定量方法、试剂及试剂盒 | |
CN1230549A (zh) | 乙肝病毒表面抗原的逃逸突变蛋白 | |
CN1255540C (zh) | 一株疫苗诱导的乙型肝炎病毒株及其应用 | |
CN1172952C (zh) | 甘露聚糖肽组合物及其制备工艺和用途 | |
CN1866023A (zh) | 一种同步检测多种结核杆菌特异性分泌抗原的方法 | |
CN1874787A (zh) | 预防/治疗hbv感染和hbv介导疾病的组合物 | |
CN1212518C (zh) | 人尿中低密度脂蛋白含量酶联免疫吸附试验试剂盒及制备方法 | |
CN101078009A (zh) | 一种从矛头蝮蛇毒中提取单一成份巴曲酶的方法 | |
CN1212517C (zh) | 人尿中高密度脂蛋白含量酶联免疫吸附试验试剂盒及制备方法 | |
CN1895263A (zh) | 牛磺酸在制备含有葛根素的注射剂中的应用 | |
CN1281959C (zh) | 烟草花叶病毒云南分离物tas-elisa检测试剂盒及其制备方法 | |
CN1629188A (zh) | 日本血吸虫的特异性抗原及用途 | |
CN1631876A (zh) | 丙磺舒钠、钾的制备和与β-内酰胺类抗生素组成复方针剂及其用途 | |
CN1737144A (zh) | 口蹄疫复合多表位二价核酸疫苗的构建 | |
CN1156491C (zh) | 经修饰的梅毒螺旋体外膜蛋白质,其免疫检测应用和含有它的试剂盒 | |
CN1641034A (zh) | 破伤风毒素重组抗原制备方法及其应用 | |
CN1287153C (zh) | 番茄花叶病毒云南分离物tas-elisa检测试剂盒及其制备方法 | |
CN1586604A (zh) | 一种莪术注射制剂及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
EE01 | Entry into force of recordation of patent licensing contract |
Assignee: Zhejiang Yilikang Biological Technology Co., Ltd. Assignor: Wang Xianli Contract fulfillment period: 2008.11.8 to 2018.11.7 contract change Contract record no.: 2008330002512 Denomination of invention: Preparation method of anti apoA1, apoB antibody and reagent box used for detecting apoAI, apoB Granted publication date: 20071226 License type: Exclusive license Record date: 2008.12.5 |
|
LIC | Patent licence contract for exploitation submitted for record |
Free format text: EXCLUSIVE LICENSE; TIME LIMIT OF IMPLEMENTING CONTACT: 2008.11.8 TO 2018.11.7; CHANGE OF CONTRACT Name of requester: ZHEJIANG PROVINCE YILIKANG BIOISYSTECH CO., LTD. Effective date: 20081205 |
|
ASS | Succession or assignment of patent right |
Owner name: ZHEJIANG YILIKANG BIOTECH CO., LTD. Free format text: FORMER OWNER: WANG XIANLI Effective date: 20100511 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 325011 ZHEJIANG YILIKANG CO., LTD, RESIDENTIAL QUARTER 27, HI-TECH PARK, ECONOMIC DEVELOPMENT ZONE, WENZHOU CITY, ZHEJIANG PROVINCE. TO: 325011 RESIDENTIAL QUARTER NO.27, HI-TECH PARK, WENZHOU CITY ECONOMIC AND TECHNOLOGICAL DEVELOPMENT ZONE, ZHEJIANG PROVINCE |
|
TR01 | Transfer of patent right |
Effective date of registration: 20100511 Address after: 325011, Zhejiang economic and Technological Development Zone, Wenzhou hi tech park, No. 27 community Patentee after: Zhejiang Yilikang Biological Technology Co., Ltd. Address before: 325011 Zhejiang Wenzhou economic and Technological Development Zone hi tech park, 27 District, Zhejiang Yili company Patentee before: Wang Xianli |
|
C56 | Change in the name or address of the patentee | ||
CP02 | Change in the address of a patent holder |
Address after: 325025, No. 1655, Binhai, Wenzhou economic and Technological Development Zone, Zhejiang Patentee after: Zhejiang Yilikang Biological Technology Co., Ltd. Address before: 325011, Zhejiang economic and Technological Development Zone, Wenzhou hi tech park, No. 27 community Patentee before: Zhejiang Yilikang Biological Technology Co., Ltd. |